PTC Therapeutics (NASDAQ:PTCT) VP Mark Elliott Boulding Sells 192 Shares of Stock

PTC Therapeutics, Inc. (NASDAQ:PTCT – Get Free Report) VP Mark Boulding sold 192 shares of PTC Therapeutics stock in a transaction that occurred on Friday, October 9th. The stock was sold at an average price of $64.26, for a total transaction of $12,337.92. Following the completion of the sale, the vice president owned 105,272 shares of the company’s stock, valued at $6,764,778.72. This represents a 0.18% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Mark Elliott Boulding also recently made the following trade(s):

Get PTC Therapeutics alerts:

• On Monday, October 5th, Mark Boulding sold 1,638 shares of PTC Therapeutics stock. The shares were sold at an average price of $64.03, for a total transaction of $104,881.14.
• On Tuesday, October 6th, Mark Boulding sold 435 shares of PTC Therapeutics stock. The shares were sold at an average price of $64.16, for a total transaction of $27,909.60.
• On Monday, August 17th, Mark Boulding sold 2,813 shares of PTC Therapeutics stock. The shares were sold at an average price of $72.57, for a total transaction of $204,139.41.

PTC Therapeutics Stock Performance

Shares of PTCT stock opened at $59.92 on Wednesday. PTC Therapeutics, Inc. has a 12-month low of $59.82 and a 12-month high of $90.87. The firm’s 50 day moving average is $68.08 and its 200 day moving average is $71.90.

PTC Therapeutics (NASDAQ:PTCT – Get Free Report) last posted its earnings results on Thursday, July 30th. The biopharmaceutical company reported $0.92 EPS for the quarter, topping analysts’ consensus estimates of $0.24 by $0.68. The company had revenue of $360.52 million during the quarter, compared to the consensus estimate of $298.63 million. The company’s revenue for the quarter was up 101.5% on a year-over-year basis. During the same period last year, the firm posted ($0.83) EPS. On average, analysts predict that PTC Therapeutics, Inc. will post 1.19 earnings per share for the current year.

Institutional Inflows and Outflows

A number of hedge funds have recently made changes to their positions in the stock. BlackRock Inc. bought a new position in PTC Therapeutics in the 2nd quarter worth $1,139,089,000. Jupiter Topco LLC bought a new stake in PTC Therapeutics during the second quarter valued at about $590,182,000. Janus Henderson Group PLC raised its holdings in PTC Therapeutics by 48.3% during the first quarter. Janus Henderson Group PLC now owns 7,193,433 shares of the biopharmaceutical company’s stock valued at $489,997,000 after acquiring an additional 2,342,101 shares during the period. William Blair Investment Management LLC bought a new stake in PTC Therapeutics during the second quarter valued at about $140,520,000. Finally, Bank of America Corp DE purchased a new position in shares of PTC Therapeutics in the second quarter valued at about $118,462,000.

Wall Street Analyst Weigh In

A number of research analysts have weighed in on the company. Wall Street Zen downgraded PTC Therapeutics from a “strong-buy” rating to a “buy” rating in a report on Saturday. Royal Bank Of Canada cut their price target on PTC Therapeutics from $85.00 to $75.00 and set a “sector perform” rating for the company in a research note on Wednesday, October 7th. Cantor Fitzgerald upped their price target on shares of PTC Therapeutics from $130.00 to $137.00 and gave the company an “overweight” rating in a research report on Tuesday, September 22nd. Zacks Research lowered shares of PTC Therapeutics from a “strong-buy” rating to a “hold” rating in a research report on Thursday, August 6th. Finally, Barclays increased their price objective on shares of PTC Therapeutics from $120.00 to $122.00 and gave the stock an “overweight” rating in a research note on Friday, August 14th. One investment analyst has rated the stock with a Strong Buy rating, ten have issued a Buy rating, two have assigned a Hold rating and two have given a Sell rating to the company’s stock. According to MarketBeat, the stock presently has an average rating of “Moderate Buy” and an average price target of $98.25.

Get Our Latest Analysis on PTCT

PTC Therapeutics Company Profile

(Get Free Report)

PTC Therapeutics, Inc is a biopharmaceutical company focused on discovering, developing and commercializing medicines for rare diseases. Its research programs use technologies designed to address genetic and molecular causes of disease, including RNA biology, protein translation and gene therapy.

The company’s commercial portfolio includes Emflaza (deflazacort), a corticosteroid approved in the United States to treat Duchenne muscular dystrophy, and Upstaza (eladocagene exuparvovec), a gene therapy for aromatic L-amino acid decarboxylase deficiency in eligible patients.

Featured Articles

• Five stocks we like better than PTC Therapeutics
• A Chinese Rival Just Spooked Memory Stocks—How Worried Should Micron Investors Be?
• Could T-Mobile’s Satellite Competition Fears Create a Buying Opportunity?
• Surgical Precision, Sustainable Returns: Johnson & Johnson Secures Its Cash Flow Runway
• Tesla’s Robotaxi Lands in Paris—But Europe’s Real Fight Is Over Cheap EVs

Receive News & Ratings for PTC Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for PTC Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.